Related Articles Even Market-Neutral Funds Couldn’t Escape the AI Slump in October Julie Segal It’s Biopharma or Bust for the IPO Market Stephen Taub Is Fama-French Still Relevant? Theory vs. Practice in Factor Investing Sponsored by Robeco